AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34863120
Drug: Passive manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive manual therapy mobilizations
Trial: 34863122
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection waves including clinical, socio-behavioral, biological data, and in-depth interviews
Trial: 34863216
Drug: velaglucerase alfa
RxNorm normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: velaglucerase alfa 60 U/kg every 2 weeks via intravenous infusion
Trial: 34863258
Drug: C1-inhibitor (C1-INH)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (C1-INH) 6000 IU
Trial: 37488627
Drug: Sound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sound therapy
Trial: 34864883
Drug: Univariate analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Univariate analysis of sociodemographic, injury-related, treatment, and early hospital outcome variables
Trial: 34864948
Drug: Ledipasvir/Sofosbuvir (90mg/400mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir (90mg/400mg) once daily for 12 weeks
Trial: 34865085
Drug: Amitriptyline, Topiramate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline, Topiramate, or Placebo (twice daily)
Trial: 34865085
Drug: Serum drug
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum drug levels
Trial: 34865085
Drug: Self-report and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-report and pill count adherence
Trial: 34865085
Drug: Serum drug
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum drug levels at trial midpoint
Trial: 34867148
Drug: Carriers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carriers of Val/Met (G/A) or Met (A/A) alleles
Trial: 34867148
Drug: Homozygous Val
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homozygous Val (G/G) carriers
Trial: 34868050
Drug: 81mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81mg of ASA daily for 6 weeks
Trial: 34869938
Drug: Composite intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite intervention including non-hormonal pharmacotherapy for VMS, digital cognitive behavioural therapy for insomnia, self-management strategies, and partner support
Trial: 34870025
Drug: Prenatal plus
RxNorm normalized name: Prenatal Plus
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prenatal plus postnatal small-quantity lipid-based nutrient supplements (SQ-LNS)
Trial: 34870878
Drug: Xentuzumab 750
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Xentuzumab 750 mg/wk
Trial: 34870878
Drug: Xentuzumab 1000
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Xentuzumab 1000 mg/wk
Trial: 34870878
Drug: Xentuzumab 1000
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Xentuzumab 1000 mg/wk (expansion cohort)
Trial: 34871089
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) at 25 mg once daily plus two investigator-selected NRTIs
Trial: 34871178
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention at individual, team, and organizational levels; specific details on dosage and duration not provided.
Trial: 34871427
Drug: Sorghum diet
RxNorm normalized name: Sorghum
DrugBank: Sorghum (DB17914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorghum diet with lysine levels of 8.2, 12.5, and 15.7 mg.kg-1.d-1
Trial: 34871427
Drug: Reference diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference diet with L-lysine levels of 5, 8, 12, and 15 mg.kg-1.d-1
Trial: 34871570
Drug: Tafenoquine 100
RxNorm normalized name: tafenoquine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 100 mg
Trial: 34871570
Drug: Tafenoquine 150
RxNorm normalized name: tafenoquine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 150 mg
Trial: 34871570
Drug: Tafenoquine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200 mg
Trial: 34872515
Drug: Standard anti-NTM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anti-NTM treatment initiated within 3 months after diagnosis of NTM pulmonary disease
Trial: 34872549
Drug: Two-item swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-item swallowing screen (oral stereognosis and cough-reflex tests)
Trial: 34873345
Drug: Avapritinib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avapritinib, a selective KIT D816V inhibitor, starting dose of 200 mg once daily
Trial: 34873347
Drug: Avapritinib (BLU-285)
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Avapritinib (BLU-285) at doses of 30-400 mg once daily
Trial: 34873975
Drug: Trilaciclib prior
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilaciclib prior to chemotherapy
Trial: 34874228
Drug: Geriatric assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geriatric assessment (GA) including modified GA (mGA) assessing comorbidities, medications, nutritional status, basic- and instrumental activities of daily living (IADL), mobility, falls, cognition, and depressive symptoms.
Trial: 34875111
Drug: Intermediate-dose thromboprophylaxis
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose thromboprophylaxis
Trial: 34875909
Drug: Cluster 1
RxNorm normalized name: CLUSTER FIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster 1 (optimal oral health and preserved masticatory capacity)
Trial: 34875909
Drug: Cluster 2
RxNorm normalized name: CLUSTER FIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster 2 (moderate oral health and moderately impaired masticatory capacity)
Trial: 34875909
Drug: Cluster 3
RxNorm normalized name: CLUSTER FIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster 3 (poor oral health and severely impaired masticatory capacity)
Trial: 34876196
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) antibiotics
Trial: 34876408
Drug: CART therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CART therapy targeting BCMA, fractioned dose of 3×10
Trial: 34876409
Drug: Atezolizumab 1,200
RxNorm normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1,200 mg every 3 weeks
Trial: 34876419
Drug: Isocaloric toddler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric toddler milk with 1.5 g/100 kcal protein
Trial: 34876419
Drug: Isocaloric toddler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric toddler milk with 6.15 g/100 kcal protein (control)
Trial: 34876420
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin hydrochloride, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Trial: 34876420
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matching the active study drug, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Trial: 34876429
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT)-based mobile app
Trial: 34876434
Drug: ATG (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG (0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg)
Trial: 34877470
Drug: Non-FMT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-FMT treatment
Trial: 34878437
Drug: Probiotics (five-strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (five-strain probiotic capsules, 1.2 × 10^10 CFUs/d for 8 weeks)
Trial: 34878898
Drug: Lead levels
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead levels in quartile four (≥6.5 µg/dL)
Trial: 34878898
Drug: Lead levels
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead levels in quartile one (<3.4 µg/dL)
Trial: 34879833
Drug: Neopterin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neopterin (in combination with KA)
Trial: 34880013
Drug: Single infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of autologous ex vivo expanded regulatory T cells (Treg)
Trial: 34880117
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injections (ESIs) for sciatica
Trial: 34882570
Drug: Intranasal racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal racemic ketamine hydrochloride administered twice per week for 4 weeks (8 sessions)
Trial: 34882570
Drug: Intranasal racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal racemic ketamine hydrochloride
Trial: 34882589
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine (3 µg intramuscular doses, two doses 28 days apart)
Trial: 34882831
Drug: Once-weekly selinexor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly selinexor, bortezomib, and dexamethasone
Trial: 34882831
Drug: Standard twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard twice-weekly bortezomib and dexamethasone
Trial: 37365439
Drug: Daily Examen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Examen
Trial: 34886910
Drug: Home therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home therapy group (HT group) directed by surgeons at post-operative appointments
Trial: 34886909
Drug: Remote nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote nutrition monitoring intervention with tailored nutritional counseling before and after surgery at 2 and 4 weeks after hospital discharge. Participants recorded nutritional intake daily for 30 days, reviewed by registered dietitians.
Trial: 34887051
Drug: PTX drug-coated
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTX drug-coated balloon angioplasty
Trial: 34887051
Drug: PTX drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTX drug-eluting stent therapy
Trial: 34887574
Drug: Immune-modulatory vaccine
RxNorm normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-modulatory vaccine (IO102/IO103) combined with nivolumab
Trial: 34887772
Drug: Evolocumab added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab added to moderate-intensity statin therapy
Trial: 34888043
Drug: Combined Surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Surgical and Injection of alcohol Treatment (COSIT), mean alcohol volume 72.0 mls, mean follow-up duration 16 months.
Trial: 34888394
Drug: Serological testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological testing for SARS-CoV-2 antibodies
Trial: 34888394
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of antibody effectiveness against variants
Trial: 34889232
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (200 mg/day and 400 mg/day) and pembrolizumab (200 mg every 3 weeks)
Trial: 34889407
Drug: Novel therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel therapies for acute myeloid leukemia (AML)
Trial: 34889746
Drug: CBT-i Coach
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-i Coach app with adjunctive physical activity (PA)
Trial: 34889776
Drug: Combined clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined clinical audits and low-dose, high-frequency (LDHF) in-service training for 6 months
Trial: 34889775
Drug: Just-in-time adaptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Just-in-time adaptive intervention group (Fitbit use, daily HRQOL reports, personalized push notifications for 3 months)
Trial: 34889775
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Fitbit use, daily HRQOL reports for 3 months without personalized feedback)
Trial: 34890832
Drug: Ceritinib (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceritinib (≥ 300 mg)
Trial: 34893524
Drug: Intravenous enadenotucirev
RxNorm normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enadenotucirev plus paclitaxel
Trial: 34893524
Drug: Intraperitoneal enadenotucirev
RxNorm normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal enadenotucirev monotherapy
Trial: 34893771
Drug: Ciltacabtagene autoleucel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene autoleucel BCMA-targeted CAR-T cell therapy
Trial: 34893952
Drug: All procedures
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All procedures and treatments
Trial: 34894221
Drug: RTS,S/AS01E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E vaccine (3 priming doses)
Trial: 34894221
Drug: RTS,S/AS01E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E vaccine (annual booster dose)
Trial: 34894221
Drug: RTS,S/AS01E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E vaccine (2nd booster dose)
Trial: 34894221
Drug: RTS,S/AS01E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E vaccine (post-vaccination antibody response)
Trial: 34894235
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine (CoronaVac), two doses administered at D0 and D28.
Trial: 34894235
Drug: MMF monotherapy
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF monotherapy in SSc patients.
Trial: 34894681
Drug: JNK inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNK inhibitors with increased JNK1 bias, specifically a novel series of 2,4-dialkylamino-pyrimidine-5-carboxamides
Trial: 34894681
Drug: Oral dosing
RxNorm normalized name: oral dosing devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of optimized JNK inhibitors
Trial: 34895133
Drug: CGRP antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP antibodies treatment for 3 months
Trial: 34895181
Drug: Vortioxetine 10-20
RxNorm normalized name: vortioxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10-20 mg over 12 weeks
Trial: 34895190
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment or Open Reduction Internal Fixation (ORIF)
Trial: 34895259
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of autologous cells
Trial: 34895290
Drug: IVIG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d) + prednisolone (2 mg/kg/d with a maximum dose of 60 mg tapered over 15 days after normalization of C-reactive protein concentration)
Trial: 34895290
Drug: IVIG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin (30 mg/kg/d)
Trial: 34895750
Drug: Oral Anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Anticoagulants (OACs)
Trial: 34895750
Drug: Vitamin-K-Antagonists (VKAs)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-K-Antagonists (VKAs)
Trial: 34898139
Drug: LentiGlobin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LentiGlobin infusion
Trial: 34899612
Drug: 0.20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg/kg biweekly PEG-rhGH
Trial: 34899612
Drug: 0.20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg/kg once-weekly PEG-rhGH
Trial: 34899612
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg daily rhGH
Trial: 34901464
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% moxifloxacin plus topical placebo plus sham CXL
Trial: 34901464
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus sham CXL
Trial: 34901464
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% moxifloxacin plus difluprednate 0.05% plus CXL
Trial: 34901797
Drug: Ixazomib 4mg
RxNorm normalized name: IXAZOMIB 4MG CAP
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib 4mg weekly for 24 weeks
Trial: 34901797
Drug: Ixazomib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib treatment
Trial: 34901885
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine (3 μg in 0.5 mL, intramuscular injection) administered on day 0 and day 28
Trial: 34902265
Drug: Grazoprevir (GZR)
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg daily for 12 weeks
Trial: 34902800
Drug: Deep sedation
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sedation with 10 mg/kg/h Propofol and nasal oxygen 0.3 ml/kg/min
Trial: 34903176
Drug: Crystalloids (80%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloids (80% balanced solutions)
Trial: 34903251
Drug: Virtual reality-enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-enhanced personal construct therapy (PCT-VR)
Trial: 34903251
Drug: Personal construct
RxNorm normalized name: Alstonia constricta bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal construct therapy (PCT)
Trial: 34903452
Drug: RO4929097 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO4929097 in combination with exemestane
Trial: 34903842
Drug: CAN04 (1.0-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN04 (1.0-10.0 mg/kg weekly)
Trial: 34905086
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) via mesenteric injection
Trial: 34906130
Drug: Multi-disciplinary education
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-disciplinary education program and Tai Chi exercise (Baduanjin), 4-week program with 2-h weekly talks and 1-h Tai Chi class.
Trial: 34906208
Drug: Pharmacist-guided pre-emptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-guided pre-emptive pharmacogenetic testing to support clinical decision making on antidepressant selection and dosing.
Trial: 34906208
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (antidepressant pharmacotherapy selected by the treating physician according to current treatment guidelines without knowledge of PGx test results).
Trial: 34906248
Drug: Agitated local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agitated local anesthetic solution injected through the catheter with color Doppler ultrasound visualization.
Trial: 34907058
Drug: Weekly self-reported
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly self-reported illness prevalence